For as long as medicine has existed, cancers have ravaged humanity. The search for an eventual cure has been a tremendous & tireless pursuit, selflessly undertaken by doctors, researchers, scientists & the entire healthcare community. With each passing year and the availability of sophisticated technologies, their efforts continue to go from strength to strength, expanding our means to adequately cope, manage and possibly rebuff the disease which has so often reminded us of our mortality. Up until recently, Chemotherapy, Surgeries, Radiation & Targeted Drug therapies had been the go-to for…
Read MoreTag: immuno oncology
Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021
Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute. Marketsandmarkets took this opportunity to talk…
Read MoreDiscussing the latest IO developments at the 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021
July, 08th 2021 – 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021 to be held on the 26th-29th October 2021 will host top tier institutes pharmaceutical, bio-pharmaceutical and biotechnology companies like Scancell, Regeneron Pharmaceuticals, Cancer Vaccines Ltd, Boston Immune Technologies & Therapeutics & more to deliver the key challenges and future directions in IO research and to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors The conference aims to bring together 25+ industry thought leaders & 200+ attendees from pharmaceutical and…
Read More“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”- A brief discussion with Juan Perez Villar, CEO, LeadArtis.
Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid tumors at Leadartis. He advanced the company from start to capitalize on the immuno-oncology (IO) market. Evaluated and repositioned the platform technology to create IO bispecific antibody dominance and created a proprietary next generation product…
Read MoreHéctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”
Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic antibodies in murine models of human autoimmune diseases. After obtaining his Ph.D., he combined two postdoctoral grants in Barcelona (Metastasis and Transformation group in Bellvitge Biomedical Research Center) and in Valencia (Autoimmune Pathology Lab in…
Read MoreDr. William Williams of Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer
Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into the clinic and established proof of concept in several disease areas. At GlaxoSmithKline he worked to bring several molecules into the clinic, ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug…
Read MoreJyoti Chandok from Concordia University, Canada speaks about ‘Factors leading to the increase in demand POCT tech and challenges in upholding Quality Standards.’
Jyoti Chandok is a seasoned professional who has been working in the healthcare sector for over 19 years. She has fulfilled several roles specializing in patient care including phlebotomy, blood analysis for hematology, immunology, genetics, and specialized method development for HIV drug-level testing using mass spectrometry. Currently, Jyoti is an Assistant Chief Medical Technologist of Point-of-Care at the McGill University Health Center (MUHC) in Montreal, Quebec, Canada. She holds a B.Sc. in Cell and Molecular Biology from Concordia University and is an active member of both the Ordre professionnel des…
Read MoreSpeaker Interview with Sebastien Tabruyn for the 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). After 10 years of experience as Project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 as Head of Molecular Biology and Oncology. Sebastien Tabruyn published 30 peer-reviewed publications in the field of Oncology, Angiogenesis, Inflammation and Immunity In a recent interview with MarketsandMarkets, Mr. Sebastien Tabruyn shared his thoughts on the current challenges that…
Read MoreWhat do MNM Analysts have to say about the Immuno Oncology Market?
Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC’s, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case…
Read MoreSpeaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and located in New-York. There, he leads the three early pipeline programs, including a novel irreversible BTK inhibitor, and anti-PD-L1 monoclonal antibody and a bispecific antibody directed against CD19 and CD47. All three assets have entered…
Read More